Microvascular angina and hypertension: a case report

Angina pectoris is one of the most frequent reasons for presentation in the emergency department worldwide and in half of these patients, especially in the young ones, coronary arteries are normal or have non-obstructive stenoses. First described as a clinical entity in 1988, microvascular angina now has precise criteria of diagnosis: symptoms of myocardial ischemia, absence of obstructive coronary artery disease and impaired coronary microvascular function (reduced coronary flow reserve, coronary microvascular spasm, increased microvascular resistance and/or coronary “slow flow” phenomenon). It is frequently associated with cardiovascular risk factors, including arterial hypertension, even in the absence of overt atherosclerotic disease. We present a case of a young female with typical rest angina; electrocardiogram changes are suggestive of myocardial ischemia and normal epicardial coronary arteries in the context of untreated hypertension. She received guideline medical treatment and we presented the patient’s inhospital evolution and at 6-month follow-up visit. Current recommendations for diagnosis, treatment and prognosis of microvascular angina are also discussed.

[1]  F. Crea,et al.  Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group , 2021, European heart journal.

[2]  A. Astrup,et al.  Comprehensive treatment of microvascular angina in overweight women – a randomized controlled pilot trial , 2020, PloS one.

[3]  A. Sinusas,et al.  Prevalence and characteristics of coronary microvascular dysfunction among chest pain patients in the emergency department , 2020, European heart journal. Acute cardiovascular care.

[4]  Marco Valgimigli,et al.  2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. , 2019, European heart journal.

[5]  E. Prescott,et al.  Diagnosis of coronary microvascular dysfunction in the clinic. , 2020, Cardiovascular research.

[6]  S. Im,et al.  Heart rate recovery and blood pressure response during exercise testing in patients with microvascular angina , 2019, Clinical Hypertension.

[7]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[8]  J. Kastrup,et al.  Coronary Microvascular Function and Cardiovascular Risk Factors in Women With Angina Pectoris and No Obstructive Coronary Artery Disease: The iPOWER Study , 2016, Journal of the American Heart Association.

[9]  Puja K. Mehta,et al.  Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy , 2015, Nature Reviews Cardiology.

[10]  A. Nelson,et al.  Clopidogrel improves microvascular endothelial function in subjects with stable coronary artery disease. , 2014, Heart, lung & circulation.

[11]  Carl J Pepine,et al.  Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. , 2010, Journal of the American College of Cardiology.

[12]  F. Crea,et al.  Coronary microvascular dysfunction. , 2013, The New England journal of medicine.

[13]  E. Picano,et al.  Effect of simvastatin on endothelial function in cardiac syndrome X patients. , 2004, The American journal of cardiology.

[14]  B. Strauer,et al.  Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. , 2000, Hypertension.

[15]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.

[16]  J. Kaski,et al.  Microvascular angina and systemic hypertension , 2016 .

[17]  M. Avdičová,et al.  Prevalence of metabolic syndrome, insulin resistance, and microvascular angina pectoris in 500 consecutive patients referred to coronarography. , 2013, Endocrine regulations.